Annovis Bio (ANVS) Q2 2025 earnings summary

Executive summary

• Lead drug candidate buntanetap advanced in clinical development for Alzheimer's and Parkinson's, with recent positive Phase 2/3 and Phase 3 data and ongoing pivotal Phase 3 AD trial initiated in February 2025, now enrolling at 76 U.S. sites with over 400 patients screened and 38 dosed.

• No product revenue to date; operations focused on R&D and clinical trials, with continued net losses and negative cash flows from operations.

• Presented four scientific posters at AAIC 2025 and completed global IP transfer for crystal buntanetap.

• Strengthened clinical and statistical leadership with new Director of Biostatistics.

Financial highlights

• Net loss of $6.2 million for Q2 2025, compared to $5.0 million in Q2 2024; net loss of $11.8 million for the six months ended June 30, 2025, versus $6.1 million in the prior year period.

• Cash and cash equivalents of $17.1 million as of June 30, 2025, up from $10.6 million at year-end 2024, expected to fund operations into Q1 2026.

• R&D expenses were $5.2 million in Q2 2025 (down $0.6 million), and G&A expenses were $1.1 million (down $0.9 million).

• Net loss per share improved to $0.32 (basic and diluted) for Q2 2025, compared to $0.44 in Q2 2024.

• No product revenue recognized; all income derived from financing activities and interest.

Outlook and guidance

• Cash runway expected through Q1 2026; management plans to raise additional capital via equity, debt, or other alternatives.

• Focus remains on completing Phase 3 enrollment as planned and advancing the Parkinson's program, with further updates expected.

• Ongoing pivotal Phase 3 AD trial may support NDA filing after 6-month symptomatic period; additional capital needed for continued development.